TRADD

A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe

Retrieved on: 
Monday, January 16, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Degenerative disease, TRADD, Biomedical Research, Automotive Supplier Innovation Program, Immunosuppression, Inflammation, HBI, URL, Eastern Standard, Lymphocyte, Antibody, PD-1, Vaccine, Nobel, Innovation

Part of the findings from the above research was published in "Science Immunology**" issued on January 13, 2023 (Eastern Standard Time).

Key Points: 
  • Part of the findings from the above research was published in "Science Immunology**" issued on January 13, 2023 (Eastern Standard Time).
  • Meiji Seika Pharma and FBRI are working together to develop the above PD-1 agonist monoclonal antibody as therapeutic candidate for autoimmune diseases.
  • "Anti-PD-1 agonist antibody" is expected to be applied as a novel therapeutic for inflammatory diseases such as autoimmune diseases caused by excessive immune reactions.
  • Meiji Seika Pharma and FBRI continue to progress the joint research on "anti-PD-1 agonist antibody" and strive to the early contribution of this antibody as a therapeutic agent for autoimmune diseases.

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

Retrieved on: 
Wednesday, January 18, 2023
MSD, Headquarters, TRADD, PRISM, Nivolumab, ASCO, Esophageal cancer, Stomach, Colorectal cancer, Pharmacokinetics, Safety, FDA, CBP, American Society of Clinical Oncology, Senior, Research, Gastrointestinal cancer, CREB-binding protein, Eisai, Patient, Merck Sharp & Dohme Federal Credit Union, Merck & Co., Society, LEAP, Medical imaging, Pharmaceutical industry, Merck

Based on these additional analyses, further investigation of safety, preliminary efficacy, pharmacokinetics and biomarker analyses of E7386 is ongoing using two dose levels in the expansion part.

Key Points: 
  • Based on these additional analyses, further investigation of safety, preliminary efficacy, pharmacokinetics and biomarker analyses of E7386 is ongoing using two dose levels in the expansion part.
  • Additional presentations on Eisai's oncology pipeline showcase Eisai's investigational compound, E7389- LF, a new liposomal formulation of eribulin, in combination with nivolumab in patients with solid tumors.
  • Efficacy and safety were evaluated in expansion cohorts, including an esophageal cancer cohort (NCT04078295; Abstract: #337) and a gastric cancer cohort (NCT04078295; Abstract: #339).
  • To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, PDX, Patient, Syngenic, DNA repair, DNA, CMC, Melanoma, Actinium-225, Dosimetry, Optimism, Annual report, SPLASH, TRADD, MCRPC, Neoplasm, Molecular imaging, Cell death, Cancer, RLT, Prostate cancer, Clinical trial, FAP, Immunotherapy, Safety, Pharmaceutical industry, Tolerability

INDIANAPOLIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today released new preclinical data from the Company’s pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT2004.

Key Points: 
  • The preclinical study focused on assessing the potential of the lead candidate in the PNT2004 clinical program, 177Lu-PNT6555, in combination with anti-PD-1 immunotherapy.
  • The CT26-mFAP tumor model used expresses low levels of FAP, grows aggressively, and is insensitive to anti-PD-1 immunotherapy.
  • The study found that combination treatment with 177Lu-PNT6555 and anti-PD-1 resulted in a significant survival benefit, as compared to either treatment independently.
  • The new preclinical data from the study can be found in an updated investor presentation available on the investors section of the Companys website.

IVD Raw Materials Global Market Report 2022: Rise in the Use Point-of-Care Diagnostics Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Health, Biotechnology, Cardiovascular disease, FDA, Blood, Immunoglobulin G, Marketing, Enzyme, Nephrology, Geography, Antigen, Infection, HIV/AIDS, Immunoglobulin M, PCR, Patient, US, Severe acute respiratory syndrome coronavirus 2, Intussusception (medical disorder), Cancer, Degenerative disease, IVD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TRADD, Diabetes, Growth, Conditional sentence, COVID-19, Roche, Diagnosis, Health, Abbott, Food, Antibody, Medical device, Pharmaceutical industry

It profiles key players in the global IVD raw materials market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.

Key Points: 
  • It profiles key players in the global IVD raw materials market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • The global IVD raw materials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global IVD raw materials market.
  • Global IVD Raw Materials Market By Product:

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Friday, October 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Friday, October 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel

Retrieved on: 
Thursday, August 25, 2022
Machine learning, Novartis, Patient, University, CEO, Cancer, Frontier, SAN, Disease, Precision medicine, Proteome, R, LinkedIn, Berkeley, Lung, PARP, KRAS, GLOBE, Â, Law, Twitter, Mutation, Amgen, Tislelizumab, BTK, TRADD, Pharmaceutical industry, Chiron, BeiGene

Prior to joining Frontier, Mr. Dizon was the assistant general counsel and chief compliance officer at BeiGene, Ltd., and was responsible for global compliance, healthcare (R&D and commercial) law, data privacy, employment law, enterprise risk management, and litigation. While at BeiGene, he supported 30+ clinical studies globally, resulting in more than a dozen regulatory approvals for BeiGene products, including tislelizumab (anti-PD-1 monoclonal antibody, pamiparib (PARP inhibitor), and zanubrutinib (BTK inhibitor). In addition, he collaborated closely with BeiGene research and development, commercial and business development teams, as well as external business partners, on multiple joint development and co-promotion collaborations, including partnerships with Celgene/BMS, Amgen and Novartis generating more than $3 billion in value for BeiGene. Prior to BeiGene, Mr. Dizon served in various legal leadership roles at both large pharmaceuticals and small biotechs -- such as Chiron, Novartis, Affymax, Actelion, Relypsa and Prothena Biosciences -- where he was able to help bring new therapies to market for patients with various cardiovascular, chronic kidney, lung and cancer conditions. Mr. Dizon obtained his J.D. from the University of California Hastings College of Law and completed his undergraduate studies at the University of California at Berkeley.

Key Points: 
  • Prior to joining Frontier, Mr. Dizon was the assistant general counsel and chief compliance officer at BeiGene, Ltd., and was responsible for global compliance, healthcare (R&D and commercial) law, data privacy, employment law, enterprise risk management, and litigation.
  • Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable.
  • Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer.
  • For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter .

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Retrieved on: 
Monday, August 8, 2022
GPP, U.S. Securities and Exchange Commission, SHM, Forward-looking statement, Inflammation, GLOBE, R, Immune system, Private Securities Litigation Reform Act, Investment, HARP, GSK, IND, Security (finance), Hidradenitis suppurativa, TRADD, Alopecia areata, SAN, Șaeș, Therapy, Safety, Collaboration, G&A, Research, Goal, Nasdaq, Toxic epidermal necrolysis, Medical device, Pharmaceutical industry, Vaccine, Online gambling

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.

Key Points: 
  • SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.
  • We anticipate top-line data from the HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa in Q3 2022.
  • Cash, cash equivalents and investments totaled $572.1 million as of June30, 2022, compared to $615.2 million as of December31, 2021, for a decrease of $43.1 million.
  • The increase was due primarily to $3.8 million of costs incurred from personnel changes in the first quarter of 2022 and non-cash stock compensation expense.

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Friday, August 5, 2022
GPP, SHM, Inflammation, GLOBE, Wedbush Securities, GSK, TRADD, SAN, Therapy, Webcast, Nasdaq, Conference, Immune system, Vaccine

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m.

Key Points: 
  • SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m.
  • A live audio webcast of the presentation will be available on the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events .
  • A replay of the webcast will be available for 90 days following the event.
  • AnaptysBiois a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
Conference, Inflammation, Webcast, SHM, Nasdaq, GLOBE, GPP, Immune system, SAN, TRADD, GSK, Vaccine

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m.

Key Points: 
  • SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m.
  • A live audio webcast of the presentation will be available on the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events .
  • A replay of the webcast will be available for 90 days following the event.
  • AnaptysBiois a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.